Home »
Academic Articles »
C »
Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension
Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension
Dalia D. Hadi
(Department of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad Iraq)
Mohammed Dheyaa Marsool Marsool
(Department of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad Iraq)
Ali Dheyaa Marsool Marsool
(Department of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad Iraq)
Neel Vora
(Department Internal Medicine B.J. Medical College Ahmedabad India)
Sajjad G. Al‐Badri
(Department of Internal Medicine University of Baghdad, College of Medicine Baghdad Iraq)
Nabeel H. K. Al‐Fatlawi
(Department of Internal Medicine University of Baghdad, College of Medicine Baghdad Iraq)
Ameer F. Abbas Al Wssawi
(Department of Internal Medicine University of Al‐Qadisiyah College of Medicine Diwaniya Iraq)
Abdullah M. T. Al‐Ibraheem
(Department of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad Iraq)
Khadija A. Hamza
(Department of Internal Medicine Al‐Kindy College of Medicine, University of Baghdad Baghdad Iraq)
Priyadarshi Prajjwal
(Department of Internal Medicine Bharati Vidyapeeth University Medical College Pune India)
Mohammed A. Mateen
(Department of Internal Medicine Shadan Institute of Medical Sciences Teaching Hospital and Research Center Hyderabad India)
Omniat Amir
(Department of Internal Medicine Al Manhal Academy Khartoum Sudan)
Abstract Background Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating lung disease characterized by irreversible scarring of the lungs. The cause of IPF is unknown, but it is thought to involve a combination of genetic and environmental factors. There is no cure for IPF, and treatment is focused on slowing disease progression and relieving symptoms. Aims We aimed in this review to investigate and provide the latest insights into IPF management modalities, including the potential of Saracatinibas a substitute for current IPF drugs. We also investigated the therapeutic potential of Sotatercept in addressing pulmonary hypertension associated with IPF. Materials and Methods We conducted a comprehensive literature review of relevant studies on IPF management. We searched electronic databases, including PubMed, Scopus, Embase, and Web of science. Results The two Food and Drug Administration‐approved drugs for IPF, Pirfenidone, and Nintedanib, have been pivotal in slowing disease progression, yet experimental evidence suggests that Saracatinib surpasses their efficacy. Preclinical trials investigating the potential of Saracatinib, a tyrosine kinase inhibitor, have shown to be more effective than current IPF drugs in slowing disease progression in preclinical studies. Also, Sotatercept,a fusion protein, has been shown to reduce pulmonary vascular resistance and improve exercise tolerance in patients with PH associated with IPF in clinical trials. Conclusions The advancements discussed in this review hold the promise of improving the quality of life for IPF patients and enhancing our understanding of this condition. There remains a need for further research to confirm the efficacy and safety of new IPF treatments and to develop more effective strategies for managing exacerbations.
Dalia D. Hadi, Mohammed Dheyaa Marsool Marsool, Ali Dheyaa Marsool Marsool, et al. (2023). "Idiopathic pulmonary fibrosis: Addressing the current and future therapeutic advances along with the role of Sotatercept in the management of pulmonary hypertension". Immunity, Inflammation and Disease. https://doi.org/10.1002/iid3.1079